Selected Grants
MaesTTRo A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Amyloid Transthyretin (ATTR) Amyloidosis
ResearchPrincipal Investigator · Awarded by AstraZeneca AB · 2024 - 2032A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
Clinical TrialPrincipal Investigator · Awarded by Eidos Therapeutics · 2025 - 2032ConTTRibute
Clinical TrialPrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2022 - 2032A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy
Clinical TrialPrincipal Investigator · Awarded by Eidos Therapeutics · 2025 - 2031DepleTTR-CM
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2024 - 2029Magnitude
Clinical TrialCo-Principal Investigator · Awarded by Intellia Therapeutics, Inc. · 2024 - 2029CardioTTRansform-OLE
Clinical TrialPrincipal Investigator · Awarded by Ionis Pharmaceuticals Inc · 2023 - 2028Machine Learning Guided Precision Genetic Testing for Identification of Monogenic Cardiovascular Disorders
ResearchCo Investigator · Awarded by National Heart, Lung, and Blood Institute · 2024 - 2028An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
Clinical TrialPrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2025 - 2028Attribute OLE
Clinical TrialPrincipal Investigator · Awarded by Eidos Therapeutics · 2022 - 2027REVEAL
Clinical TrialPrincipal Investigator · Awarded by Brigham and Women's Hospital · 2025 - 2027Strategy to Improve Patient Outcomes by Silencing TTR Formation in ATTR-CM
Clinical TrialPrincipal Investigator · Awarded by Ionis Pharmaceuticals Inc · 2020 - 2026Helios-B: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Outcomes, Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)
Clinical TrialPrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2020 - 2026The Cardiac Amloidosis Registry Study
ResearchPrincipal Investigator · Awarded by Cedars Sinai Medical Center · 2021 - 2025ANNAMYCIN III - Acute Myeloid Leukemia
Clinical TrialPrincipal Investigator · Awarded by Moleculin Biotech, Inc. · 2022 - 2025MB-107 Annamycin II Sarcoma
Clinical TrialPrincipal Investigator · Awarded by Moleculin Biotech, Inc. · 2021 - 2024AG10-301 ATTRIBUTE
Clinical TrialPrincipal Investigator · Awarded by Eidos Therapeutics · 2019 - 2023CHEPRI: Chronology of Effects of Patisiran on Cardiac Amyloidosis
Clinical TrialPrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2021 - 2023Cardiac Amyloid: The Duke Experience
ConferencePrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2022 - 2022AG10 ATTR-CM R6MWT
Clinical TrialPrincipal Investigator · Awarded by Eidos Therapeutics · 2021 - 2022Attract Extension-- Endeavor Extension Study
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2016 - 2021A Phase III, Open-Label, Multicenter Trial to Evaluate Ejection Fraction, End-Diastolic and End-Systolic Volumes, by Unenhanced and DEFINITY®-enhanced 2D-Echo and Magnetic Resonance Imaging
Clinical TrialPrincipal Investigator · Awarded by Lantheus Medical Imaging · 2019 - 2021A Phase III, Open Label, Multicenter Trial to Evaluate Ejection Fraction, End Diastolic and End Systolic Volumes, by Unenhanced and DEFINITY enhanced 2D-Echo and Magnetic Resonance Imaging
Clinical TrialPrincipal Investigator · Awarded by Lantheus Medical Imaging · 2018 - 2020ISCHEMIA: International Study of Comparative Health Effectiveness with Medical and Invasive Approaches
Clinical TrialPrincipal Investigator · Awarded by New York University School of Medicine · 2014 - 2020EXCITE
ResearchPrincipal Investigator · Awarded by Sloan Kettering Institute · 2018 - 2019Educational Preceptorship Program
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Pfizer, Inc. · 2019 - 2019International Study of Comparative Health Effectiveness with Medical and Invasive Approaches
Clinical TrialPrincipal Investigator · Awarded by New York University School of Medicine · 2014 - 2018SCUSF 0806 Phase II placebo--controlled trial of lisinopril and Coreg
ResearchCo Investigator · Awarded by University of South Florida · 2013 - 2014External Relationships
- Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca
- Alnylam Pharmaceutical, Inc.
- Eidos Therapeutics/BridgeBio
- HOPO Therapeutics
- IONIS-AstraZeneca Pharmaceuticals
- Moleculin Biotech Inc.
- PRIME Education, LLC
- Pfizer Inc.
- SpringWorks Therapeutics
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.